In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Cg Oncology Inc (NASDAQ: CGON) closed the day trading at $26.14 down -0.68% from the previous closing price of $26.32. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 0.63 million shares were traded. CGON stock price reached its highest trading level at $26.365 during the session, while it also had its lowest trading level at $25.705.
Ratios:
For a better understanding of CGON, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 30.97 and its Current Ratio is at 30.97. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 02, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $41.
On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $23.Scotiabank initiated its Sector Perform rating on April 16, 2025, with a $23 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 17 ’25 when POST LEONARD E sold 2,000 shares for $28.00 per share. The transaction valued at 56,000 led to the insider holds 0 shares of the business.
LEONARD E POST bought 2,000 shares of CGON for $52,160 on Jul 17 ’25. On May 21 ’25, another insider, POST LEONARD E, who serves as the Director of the company, sold 1,000 shares for $28.00 each. As a result, the insider received 28,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 1992529152 and an Enterprise Value of 1305131520. For the stock, the TTM Price-to-Sale (P/S) ratio is 3018.98 while its Price-to-Book (P/B) ratio in mrq is 2.83. Its current Enterprise Value per Revenue stands at 1971.498 whereas that against EBITDA is -9.714.
Stock Price History:
The Beta on a monthly basis for CGON is 0.87, which has changed by -0.2095555 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $40.47, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is 0.02%, while the 200-Day Moving Average is calculated to be -8.49%.
Shares Statistics:
Over the past 3-months, CGON traded about 1.27M shares per day on average, while over the past 10 days, CGON traded about 1106520 shares per day. A total of 76.22M shares are outstanding, with a floating share count of 44.88M. Insiders hold about 41.12% of the company’s shares, while institutions hold 67.97% stake in the company. Shares short for CGON as of 1751241600 were 11294559 with a Short Ratio of 8.92, compared to 1748563200 on 12337970. Therefore, it implies a Short% of Shares Outstanding of 11294559 and a Short% of Float of 15.689998999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Cg Oncology Inc (CGON) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.39 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.57 and -$2.07 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.79, with 8.0 analysts recommending between -$0.84 and -$3.58.
